Tracers / [18F]FBNA
[18F]FBNA
Also written as [18F]FBNA
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- 2-nitroimidazole derivative (18F-labeled analogue of benznidazole)
- Target / mechanism
- Bioreductive trapping in hypoxic tissue associated with HIF-1α expression (2-nitroimidazole hypoxia marker) PMID 37651917
- Clinical application
- Breast cancer (triple-negative and estrogen receptor-positive) xenograft models for hypoxia imaging PMID 37651917
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [18F]FBNA, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]FBNA.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with F-18.